Financial Data and Key Metrics Changes - Research and development revenue for Q1 2025 rose 6% to $6,700,000 from $6,300,000 in Q1 2024, reflecting increased activity under the BARDA Project BioShield contract [12] - Gross margin increased to 47.2% from 46.6% in Q1 2024 due to a higher concentration of direct labor as a component of revenue [12] - General and administrative expenses decreased significantly from $5,100,000 in Q1 2024 to $4,100,000 in Q1 2025, primarily due to a focus on the BARDA contract and cost-cutting measures [12] - Operating loss for Q1 2025 was $896,000 compared to a net loss of $2,100,000 in Q1 2024 [13] - The company reported net income of $2,900,000 in Q1 2025, a significant improvement from a net loss of $3,200,000 in the same quarter last year [13] - Cash and cash equivalents totaled $14,100,000 as of March 31, 2025, up from $5,200,000 on December 31, 2024 [14] Business Line Data and Key Metrics Changes - The company is focused on advancing its DeepView technology and preparing for FDA submission, which is a key milestone for its product line [5][6] - The DeepView Snapshot M handheld device is in development, with two prototypes successfully assembled [9] Market Data and Key Metrics Changes - The company reiterated its revenue guidance for 2025 at approximately $21,500,000, which does not include contributions from sales of the DeepView system in the UK or Australia [14] Company Strategy and Development Direction - The company is transitioning from a research-focused organization to a commercial entity with a well-defined business focus for 2025 and beyond [4] - The primary goal is to achieve FDA de novo classification submission by the end of Q2 2025, which is critical for future growth [5] - The company is also developing its healthcare intellectual property subsidiary, Spectral IP, which is in the SEC registration process for an initial public offering [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the revenue guidance and noted that the first quarter's strong performance reflects efforts to focus on the FDA submission [18][19] - The company has had over 10 pre-submission meetings with the FDA, which have been constructive and supportive [22][23] - Management is optimistic about the prospects for growth and development, emphasizing the importance of the BARDA partnership [40][41] Other Important Information - The company completed a debt financing agreement of up to $15,000,000, with an initial drawdown of $8,500,000, and raised approximately $2,700,000 in equity financing [7][8] - The burn validation study results, which utilized over 340 billion clinically validated data points, demonstrated the effectiveness of the DeepView technology [6] Q&A Session Summary Question: Guidance on revenue expectations - Management indicated that the revenue guidance of $21,500,000 seems reasonable, although they may restate it if performance continues to exceed expectations [18][19] Question: Preparation for FDA submission - Management highlighted a strong relationship with BARDA and noted that they have been working closely with the FDA to de-risk the submission process [22][23] Question: General administrative expenses outlook - Management anticipates general and administrative expenses to remain consistent with Q1 results, focusing on operational efficiencies [32][33] Question: Development of Snapshot M device - Management confirmed that while they are focused on the FDA submission, they are also advancing the development of the Snapshot M device for military use [38][41] Question: Future relationships with the DoD - Management acknowledged the importance of developing relationships with the DoD and emphasized ongoing efforts to improve the Snapshot M device [49][50]

Financial Data and Key Metrics Changes - The company reported total revenues of approximately $555 million for Q1 2025, which included cabozantinib franchise net product revenues of $513.3 million, a 36% year-over-year increase from $378 million in Q1 2024 [7][13] - Non-GAAP net income for Q1 2025 was approximately $179.6 million, or $0.64 per share basic, compared to $159.6 million GAAP net income [16] - The company increased its full-year 2025 net product revenue guidance to $2.05 billion to $2.15 billion, reflecting a $100 million increase from previous guidance [18] Business Line Data and Key Metrics Changes - The U.S. cabozantinib franchise net product revenues grew 36% year-over-year to $513 million [7] - Global cabozantinib franchise net product revenues were approximately $680 million in Q1 2025, compared to $559 million in Q1 2024 [7] - The gross-to-net for the cabozantinib franchise in Q1 2025 was 28.9%, higher than the previous quarter, primarily due to increased PHS and 340B volumes [13] Market Data and Key Metrics Changes - CABOMETYX grew its market share from 40% to 44% in the TKI market basket, with TRx volume growing 18% year-over-year [20][21] - New prescription share for CABOMETYX increased from 38% to 43%, with NRx volume growing 27% year-over-year [22] - The oral market opportunity for neuroendocrine tumors in 2025 is forecasted to be approximately $1 billion in the U.S. [24] Company Strategy and Development Direction - The company aims to build a multi-compound, multi-franchise oncology enterprise, focusing on improving the standard of care for cancer patients [4][5] - The launch of CABOMETYX in neuroendocrine tumors is seen as a significant commercial opportunity, with expectations of rapid establishment as a market leader [20][25] - The company is advancing ZANZA as its next oncology franchise opportunity, with several pivotal trials expected to report data in the second half of 2025 [10][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance of CABOMETYX and the potential for new indications to drive further growth [6][9] - The company is focused on advancing new molecules from its pipeline and expects to file up to three new INDs in 2025 [11][34] - Management highlighted the importance of capital allocation, balancing investments in R&D, business development, and share repurchases [12][86] Other Important Information - The company repurchased approximately $289 million of its shares during Q1 2025, with a remaining authorization of $5.5 million under the previous buyback plan [17] - The company is focused on late-stage assets in GU and GI oncology for business development opportunities [72] Q&A Session Summary Question: What has been driving CABOMETYX growth? - The company noted significant growth in market share and volume, particularly in frontline RCC, driven by positive physician feedback and updated data from CheckMate 9ER [42][46] Question: What are the expectations for the NET launch? - Management indicated that it is early days for the NET launch, with positive prescriber excitement and new prescriptions being tracked closely [49][54] Question: What is the impact of Medicare Part D redesign? - The company reported minimal impact from the redesign, with a roughly equal split between commercial and Medicare business [74][78] Question: What is the company's approach to business development? - The company remains open to business development opportunities, focusing on high-conviction assets that align with its oncology franchise [68][70]

Fathom (FTHM) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good day, everyone, and welcome to the Fathom Holdings, Inc. First Quarter twenty twenty five Conference Call. At this time, all participants have been placed on a listen only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Paul Kuntz. Sir, the floor is yours. Speaker1 Thank you and good afternoon. Welcome to Fathom Holdings first quarter t ...

Electromed (ELMD) Q3 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings, and welcome to the Electromed Third Quarter Fiscal twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce you to your host, Mike Kavanaugh, Investor Relations. Thank you, Mike. You may begin. Speaker1 Good afternoon, and thank you for joi ...

Surf Air Mobility (SRFM) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 I would now like to turn the call over to Sam Levinson, Investor Relations. Please go ahead. Speaker1 Thank you, operator. Welcome to Surf Air Mobility's first quarter twenty twenty five earnings call. I'm joined today by Deanna White, Chief Executive Officer and Chief Operating Officer and Oliver Reeves, Chief Financial Officer. Our earnings release can be found on the SEC EDGAR website and on our Surf Air Mobility Investor Re ...

Pixelworks (PXLW) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 a reminder, this conference call is being recorded for replay purposes. I would now like to turn the call over to Brett Perry with Shelton Group Investor Relations. Please go ahead. Speaker1 Thank you, Kevin. Good afternoon, and thank you for joining today's call. With me on the call are Pixelworks' President and CEO, Todd DeBonis and Chief Financial Officer, Haley Amun. The purpose of today's conference call is to supplement the info ...

Oklo (OKLO) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oklo First Quarter twenty twenty five Financial Results and Business Update Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Sam Doane, Director of Investo ...

Financial Data and Key Metrics Changes - The company reported consolidated revenue of $83.5 million for Q1 2025, a decline from $88.1 million in Q1 2024, reflecting a 12% decrease in social casino revenues and a 59% increase in iGaming revenues [6][12][14] - Adjusted EBITDA for Q1 2025 was $30.8 million, down from $32.7 million in the prior year, with an adjusted EBITDA margin of 36.9% compared to 37.1% in Q1 2024 [16] - Cash flow from operations increased to $41.1 million, up from $35.7 million in Q1 2024, indicating strong cash flow conversion [7][17] Business Line Data and Key Metrics Changes - Social casino free-to-play games generated $70.3 million in revenue, while iGaming business Super Nation generated $13.2 million, marking the highest quarterly performance since its acquisition [6][9][12] - Key monetization metrics for the social casino business improved, with ARPDAU increasing to $1.29 and payer conversion rate rising to 6.9% [8][13] Market Data and Key Metrics Changes - Super Nation's revenue growth was driven by increased investments in new player acquisition, particularly in the UK and Sweden [9][24] - The company noted that the competitive landscape for user acquisition costs has intensified due to increased spending by competitors in the sweepstakes gaming sector [41] Company Strategy and Development Direction - The company aims to maintain capital efficiency while focusing on product improvements and live operations enhancements in Double Down Casino [18] - There is an ongoing strategy to explore potential acquisitions to diversify revenue and cash flow sources [10][30] - The company has decided not to launch a new match-three style game after extensive testing, emphasizing a cautious approach to new game development [10][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the first half of 2025 presents tough comparisons due to strong performance in the prior year, but expects easier comparisons in the second half [39] - The company remains optimistic about the potential for iGaming businesses to become highly profitable at scale, with plans to continue investing in player acquisition [18][36] Other Important Information - The company transitioned to reporting financial results in accordance with IFRS, which has minor implications for financial statements compared to GAAP [4][11] - As of March 31, 2025, the company had $455.7 million in cash and short-term investments, with a net cash position of approximately $422 million [17] Q&A Session Summary Question: Trends in Super Nation's markets and major sporting events - Management noted strong returns on investment in player acquisition and highlighted the rapid payback from marketing efforts in Sweden and the UK, but indicated that there are no major event-based revenue drivers [24][27] Question: Update on M&A opportunities - The company continues to see a flow of opportunities in both iGaming and mobile gaming, with no significant changes in interest or opportunities despite macroeconomic uncertainties [30] Question: Expectations for Super Nation's growth and sales/marketing spending - Management expressed confidence in maintaining or increasing current levels of investment in player acquisition, expecting continued revenue growth from Super Nation [36] Question: Social casino business decline expectations - Management acknowledged the challenges in growing the social casino business year-over-year but indicated that comparisons will improve in the second half of the year [39] Question: User acquisition costs and competition - Management noted that user acquisition costs have risen due to competition from sweepstakes games, but it is difficult to quantify player losses to these competitors [41]

CarParts.com (PRTS) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good afternoon. At this time, all participants will be in listen only mode. Please note this call is being recorded. I would now like to pass the conference over to our host, Ryan Lockwood, Chief Financial Officer. Please go ahead. Speaker1 Hello, everyone, and thank you for joining us for the CarParts.com First Quarter 20 20 5 Conference Call. Joining me today is David Mignon, Chief Executive Officer. Before I turn it over to David ...

IRIDEX (IRIX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the First Quarter twenty twenty five IRIDEX Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Thank you. I would now like to turn the conference over to Trip Taylor of Investor Relations. You may begin. Speaker1 Thank you, and thank ...